Monday, February 13, 2012

Oxford Immunotec taps Altieri as CFO

By Patricia Resende, Correspondent

After serving two years as the chief financial officer of New Hampshire-based Salient Surgical Technologies, Richard Altieri will now take the financial reigns of another medical technology business, this time for a company in Massachusetts.

Altieri, who led the charge to take Salient public and ultimately led the company’s acquisition by Medtronic and who also played a role in the acquisition of Mitek Surgical to Johnson & Johnson, will join the executive team at Oxford Immunotec Ltd., a medical diagnostics business with offices in Marlborough and England.

Oxford Immunotec has developed T-Spot, a technology used to measure a patient’s immune response to infections and diseases such as tuberculosis. At Oxford, Altieri will be tasked with leading the company’s financial growth in the T cell measurement market.

Oxford Immunotec CEO Peter Wrighton-Smith said Altieri will be a tremendous asset to the company, in a release announcing his appointment.

Salient announced its $525 million sale to medical device giant Medtronic Inc. in July 2011. The company was co-founded as Tissuelink Medical Inc. in 1999 by then president and CEO M. Jacqueline Eastwood, who was named as a Mass High Tech All-Star in 2003.

Oxford Immunotec first landed its North American headquarters in Marlborough in 2008. In April 2010, Oxford Immunotec received the second tranche of a $26 million investment led by New Leaf Venture Partners of New York, that added New Leaf managing director Vijay Lathi to the board of directors.